An international survey of clinicians regarding their management of venous thromboembolism following the initial 3-6 months of anticoagulation
- PMID: 32592081
- DOI: 10.1007/s11239-020-02193-6
An international survey of clinicians regarding their management of venous thromboembolism following the initial 3-6 months of anticoagulation
Abstract
After an initial treatment period for venous thromboembolism (VTE), indefinite anticoagulation may be considered, depending upon individual risks. The aim of the study was to determine if there is consensus amongst clinicians that manage VTE regarding which patients require 3-6 months versus indefinite anticoagulation. The importance of VTE site and severity in decision making was also evaluated. An international survey of clinicians involved in VTE management was undertaken. Respondents were asked about long-term treatment of six patients that had completed 3-6 months initial anticoagulation. These included four cases of VTE not associated with a major reversible risk factor and two control cases; one unprovoked VTE and one VTE associated with a major reversible risk factor. For consensus, there was a pre-defined equivalence boundary whereby at least 70% of clinicians had to decide either to stop or consider indefinite anticoagulation for each case. 351 responses were collected. In the control cases, there was a ≥ 95% consensus on long-term management (stop versus indefinite anticoagulation). In three of the four test cases, there was no consensus about duration of anticoagulation. In case 3, 78% (99% confidence interval 73-84%) would stop anticoagulation after 3-6 months. When analysed by grade or specialty of doctor, a lack of consensus remained. Opinion on whether site or severity of VTE influenced decision making was variable. For patients with unprovoked VTE or VTE associated with a major transient risk factor there is treatment consensus. For the remainder, there is a lack consensus regarding the need for indefinite anticoagulation.
Keywords: Anticoagulation; Long-term management; Thrombosis; Venous thromboembolism.
References
-
- Kearon C, Akl EA, Ornleas J, Blavias A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 149:315–352 - DOI
-
- National Institute for Clinical Excellence (2015). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Clinical guideline 144. https://www.nice.org.uk/guidance/cg144 . Accessed 31 Dec 2019.
-
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, ESC Scientific Document Group et al (2019) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. https://doi.org/10.1093/eurheartj/ehz405 - DOI - PubMed
-
- Rodger MA, Le Gal G (2018) Who should get long-term anticoagulant therapy for venous thromboembolism and with what? Blood Adv 2:3081–3087 - DOI
-
- Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V et al (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor. Arch Intern Med 170:1710–1716 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical